Kidney cancer: identification of novel targets for therapy
- PMID: 16408110
- DOI: 10.1038/sj.ki.5000065
Kidney cancer: identification of novel targets for therapy
Abstract
Kidney cancer, although relatively rare when compared to other malignancies, occurs not uncommonly in patients with renal disease and is often discovered incidentally during the initial nephrologic work-up, or by the savvy clinician who is familiar with the paraneoplastic signs. While surgical approaches are generally curative when the disease is confined to the kidney, one-third of the cases that present in the metastatic form and require conventional medical therapy are associated with a truly dismal patient survival rate. In light of the emerging knowledge of the molecular mechanisms of kidney cancer oncogenesis, several novel and promising therapeutic approaches are emerging. In this review, we summarize the current state of kidney cancer diagnosis and therapy, as well as some of the novel treatments that capitalize on those newly elucidated molecular pathways that are deranged in this disease.
Similar articles
-
Molecular biology of renal cell cancer and the identification of therapeutic targets.J Clin Oncol. 2006 Dec 10;24(35):5593-600. doi: 10.1200/JCO.2006.08.8948. J Clin Oncol. 2006. PMID: 17158545 Review.
-
Review article: How cells sense oxygen: lessons from and for the kidney.Nephrology (Carlton). 2009 Feb;14(1):86-93. doi: 10.1111/j.1440-1797.2008.01064.x. Epub 2009 Jan 8. Nephrology (Carlton). 2009. PMID: 19143941 Review.
-
Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.Cancer Res. 2002 Jul 1;62(13):3803-11. Cancer Res. 2002. PMID: 12097293
-
[Tumor-specific gene therapy strategy for renal cell carcinomas].Nihon Rinsho. 2006 Feb;64 Suppl 2:672-5. Nihon Rinsho. 2006. PMID: 16523975 Review. Japanese. No abstract available.
-
Hypoxia-inducible factor-1-dependent repression of E-cadherin in von Hippel-Lindau tumor suppressor-null renal cell carcinoma mediated by TCF3, ZFHX1A, and ZFHX1B.Cancer Res. 2006 Mar 1;66(5):2725-31. doi: 10.1158/0008-5472.CAN-05-3719. Cancer Res. 2006. PMID: 16510593
Cited by
-
Prediction and diagnosis of renal cell carcinoma using nuclear magnetic resonance-based serum metabolomics and self-organizing maps.Oncotarget. 2016 Sep 13;7(37):59189-59198. doi: 10.18632/oncotarget.10830. Oncotarget. 2016. PMID: 27463020 Free PMC article.
-
Combined Ibuprofen-Nanoconjugate Micelles with E-Selectin for Effective Sunitinib Anticancer Therapy.Int J Nanomedicine. 2022 Dec 6;17:6031-6046. doi: 10.2147/IJN.S388234. eCollection 2022. Int J Nanomedicine. 2022. PMID: 36510619 Free PMC article.
-
Pathway analysis of kidney cancer using proteomics and metabolic profiling.Mol Cancer. 2006 Nov 24;5:64. doi: 10.1186/1476-4598-5-64. Mol Cancer. 2006. PMID: 17123452 Free PMC article.
-
Genetic and epigenetic alterations during renal carcinogenesis.Int J Clin Exp Pathol. 2010 Dec 13;4(1):58-73. Int J Clin Exp Pathol. 2010. PMID: 21228928 Free PMC article. Review.
-
Prognostic role of microvessel density in patients with renal cell carcinoma: a meta-analysis.Int J Clin Exp Pathol. 2014 Aug 15;7(9):5855-63. eCollection 2014. Int J Clin Exp Pathol. 2014. PMID: 25337227 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical